Ruth R. Ruddle
London, ENG SM25NG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.
Journal: Investigational new drugs
Published: February 04, 2026
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.
Journal: Nature medicine
Published: December 12, 2024
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Journal: Nature
Published: May 23, 2023
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2022
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
Journal: Molecular cancer therapeutics
Published: May 19, 2021
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Journal: Cancer discovery
Published: April 30, 2020
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 24, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Journal: Cancer discovery
Published: February 15, 2020
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation.
Journal: Metabolomics : Official journal of the Metabolomic Society
Published: January 22, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 03, 2019
Last Updated: 09/26/2026